Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Focal ExAblate™ MR-Guided Focused Ultrasound (MRgFUS) Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer (OC-IRPC): Evaluation of Safety and Effectiveness

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02968784
• Other study ID #: PCa006
• Status: Terminated
• Phase: N/A
• Start date: June 2016
• Est. completion date: February 2, 2023

Study information

• Verified date: July 2020
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is intended to show that ExAblate™ MRgFUS is a safe procedure that can significantly postpone or eliminate the need of patients with organ confined intermediate risk prostate cancer to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation therapy) for their disease.

Description:

This study will evaluate the proportion of patients with organ-confined intermediate risk prostate cancer (OC-IRPC) undergoing focal ExAblate™ MRgFUS prostate treatment that will be free of clinically significant PCa which requires definitive treatment at 2 years after completion of their ExAblate™ treatment and to demonstrate the safety of focal ExAblate™ MRgFUS treatment.

Clinically significant PCa requiring definitive treatment is defined as pathology findings from whole-gland, imaging-guided, extended mapping biopsy of Gleason Score (GS) > 7

The primary efficacy endpoint in this trial, measured at 24 months with whole-gland extended imaging-guided mapping biopsy, is Response scored dichotomously for each subject as follows:

• Response = 0 ("Failure"): Positive mapping biopsy defined as Gleason Score > 7 (indicating definitive treatment) in any part of their prostate gland

• Response = 1 ("Success"): Negative mapping biopsy defined as Gleason Score < 7.

Safety of ExAblate™ treatment will be determined by evaluation of the incidence and severity of device related complications from the first treatment day visit throughout entire follow-up duration.

All adverse events will be captured and recorded. However, the safety of the ExAblate™ treatment will be defined by the incidence and severity of treatment or device related adverse events, grades III - V (CTCAE version 4.03; 2010-06-14).

Secondary Effectiveness Outcomes:

1. % of patients with negative 5-month follow-up biopsy results in the treated part of the prostate

2. Treatment effect on patients' Quality of Life (QoL), the following validated self-reported urogenital functioning assessment instruments will be used before and following treatment at pre-specified intervals.

1. Urinary symptoms - IPSS

2. Urinary continence - ICIQ-UI-SF

3. Sexual function - IIEF-15

3. PSA levels and post-treatment PSA kinetics will also be assessed

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 53
• Est. completion date: February 2, 2023
• Est. primary completion date: February 2, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• PSA = 20 ng/ml

• Histologically proven PCa on imaging-guided transrectal or transperineal extended mapping biopsy

• Patient with intermediate risk, early-stage organ-confined prostate cancer (T1a up to T2b, N0, M0) and voluntarily chooses ExAblate thermal ablation as the non-invasive treatment, who may currently be on wtachful waiting or active surveillance and not in need of imminent therapy

• Gleason Score 7 (3+4 or 4+3) based on mapping prostate biopsy with no more than 15mm cancer in maximal linear dimension in any single core

• Single hemilateral index Gleason 7 lesion identified in the prostate based on biopsy mapping with supporting MRI findings; may have secondary Gleason 6 lesion on ipisilateral or contralateral side confirmed with biopsy and/or MRI

Exclusion Criteria:

• Any Contraindication to MRI, such as: over-size limitations avoiding patient's positioning in the bore of MRI scanner, claustrophobia, implanted ferromagnetic materials or foreign objects, or known contraindication to utilization of MRI contrast agent (e.g., Gadolinium/Magnevist)

• History of prostatectomy, radiation therapy to the pelvis for any other malignancy, brachytherapy, Cryotherapy, US-guided HIFU, orchiectomy, prostate photodynamic therapy, or prostate cancer-specific chemotherapy

• Patient under androgen deprivation therapy (ADT), alpha reductase inhibitors, and/or other hormonal treatment within the past 6 months

• Any rectal disease, pathology, anomaly, injury, previous treatment, or scarring which could change acoustic properties of the rectal wall, or might prevent safe probe insertion (e.g., inflammatory bowel disease, fistula, stenosis, fibrosis, or symptomatic hemorrhoids

• History of an invasive malignancy other than basal or squamous skin cancers in the last 5 years

• Existing urethral or bladder neck contracture/stricture

• Prostatitis NIH categories I, II and III

• Implant near (<1cm) the prostate

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• ExAblate MRgFUS
ExAblate treatment of prostate cancer less than or equal to Grade 7

Locations

Country	Name	City	State
Canada	Toronto General Hospital	Toronto	Ontario
China	Beijing Hospital	Beijing	Beijing
China	Changhai Hospital of Shanghai	Shanghai	Shanghai
United Kingdom	St. Mary's Hospital	London

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Countries where clinical trial is conducted

Canada,  China,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy endpoint in this trial measured with whole-gland extended imaging-guided mapping biopsy, is Response scored dichotomously; success vs. failure	Response will be based on mapping biopsy defined by Gleason 7 Score in any part of the prostate gland	24 months post treatment
Primary	Adverse events	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	24 months post treatment
Secondary	Percent of patients with negative biopsy	% of patients with negative 5-month follow-up biopsy results in the treated part of the prostate	5 months post treatment
Secondary	Quality of Life - urinary symptoms - IPSS questionnaire score	Treatment effect on patients' Quality of Life (QoL), i.e., urinary symptoms	24 months post treatment
Secondary	Quality of Life - urinary continence - ICIQ-SF questionnaire score	Treatment effect on patients' Quality of Life, (QoL), i.e., urinary continence	24 months post treatment
Secondary	Quality of Life - sexual function - IIEF-15 questionnaire score	Treatment effect on patients' Quality of Life, (QoL), i.e.,sexual function	24 months
Secondary	Prostate Specific Antigen (PSA)	PSA levels and post-treatment PSA kinetics will be assessed	24 months post treatment